ERS International Congress 2020: highlights from the Paediatric Assembly

Cristina Ardura-Garcia1, Sara Cuevas-Ocaña2, Nadine Freitag3

  • 1Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

ERJ Open Research
|March 29, 2021
PubMed

Insights

This review highlights key advances in pediatric respiratory medicine from the ERS Congress 2020. It covers asthma, cystic fibrosis, and early life exposures impacting lung health, emphasizing early detection and multidisciplinary care.

Area of Science:

  • Pediatric Respiratory Medicine
  • Pulmonology
  • Allergy and Immunology

Background:

  • The European Respiratory Society (ERS) Paediatric Assembly reviews significant research presented at the 2020 ERS International Congress.
  • Focus areas include respiratory physiology, sleep, asthma, cystic fibrosis, infection, immunology, neonatology, and lung development.

Purpose of the Study:

  • To summarize and discuss key findings in pediatric respiratory medicine from the ERS International Congress 2020.
  • To highlight research on long-term respiratory outcomes, risk factors, and diagnostic challenges.

Main Methods:

  • Review and discussion of selected research by Early Career Members and Chairs of the ERS Paediatric Assembly.
  • Analysis of studies on lung function, disease progression, biomarkers, genetic analysis, and environmental exposures.

Main Results:

  • Long-term effects of premature birth, delivery mode, and cystic fibrosis on lung function are detailed.
  • Risk factors, phenotypes, and diagnostic challenges in pediatric asthma are presented.
  • The utility of lung clearance index for early cystic fibrosis detection and the importance of treatable traits in bronchiectasis are confirmed.
  • Impact of early-life exposures (obesity, hypoxia, pollution) on respiratory health and lung development is discussed, utilizing metabolomics and genetic analysis.

Conclusions:

  • Early detection methods like the lung clearance index are valuable for conditions such as cystic fibrosis.
  • Identifying treatable traits is crucial for managing bronchiectasis.
  • Multidisciplinary teams are essential for treating complex pediatric airway pathologies.
  • Understanding the long-term impact of early-life exposures on lung development requires advanced analytical techniques.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
114
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
85
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
80
International Nursing Organizations II01:28

International Nursing Organizations II

The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
1.2K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
76
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.1K